Ad
related to: 5α reductase inhibitor- Custom Synthesis Service
Bulk Custom Product Services.
High Quality Guarantee.
- Resources
Product Brochures, Guidelines, etc.
Covering Multiple Research Areas.
- FAQ/Technical Support
Frequently Asked Questions.
24/7 Customer Service.
- Contact Us
50,000+ Bioactive Molecules.
Sales@MedChemExpress.com
- Custom Synthesis Service
Search results
Results from the WOW.Com Content Network
5α-Reductase inhibitors (5-ARIs), also known as dihydrotestosterone (DHT) blockers, are a class of medications with antiandrogenic effects which are used primarily in the treatment of enlarged prostate and scalp hair loss.
5α-reductase inhibitors (5-ARIs), specifically finasteride and dutasteride, are medications approved by the U.S. Food and Drug Administration (FDA) for treating 2 conditions: benign prostatic hyperplasia (BPH) and androgenic alopecia (male pattern hair loss).
The class of medicines called 5-alpha reductase inhibitors (5ARIs) includes finasteride and dutasteride. These medicines treat benign prostatic hypertrophy and male pattern hair loss.
5-alpha-reductase inhibitors are a group of medicines that block the action of 5-alpha-reductase, the enzyme that converts testosterone into dihydrotestosterone.
The key role of 5α-reductase in cortisol breakdown and fat buildup has elucidated some of the side effects of 5α-reductase inhibitors. In randomized studies on human volunteers it was found that 5α-reductase inhibition through the use of dutasteride and finasteride can lead to hepatic lipid accumulation in men. [ 41 ]
Dutasteride is a selective inhibitor of 5a-reductase type 1 and 5a-reductase type 2, and appears to be an irre versible inhibitor (29). Dutasteride has a half-life of 247 hours in humans (29). Dutasteride reaches maximum effec tiveness at 1 mg -1 kg -1 day, with a peak blood concentration of 140 ng/mL (29).
5α-reductase inhibitors (5-ARIs), including finasteride and dutasteride, are approved by the U.S. Food and Drug Administration for treating benign prostatic hyperplasia and androgenic alopecia. These medications inhibit the enzyme 5α-reductase, reducing the conversion of testosterone into dihydrotestosterone, a hormone implicated in prostate ...
Competitive and specific inhibitor of Type II 5α-reductase, an intracellular enzyme that converts testosterone to 5α-dihydrotestosterone (DHT). DHT is the principal androgen responsible for stimulation of prostatic growth.
High activity of 5alpha-reductase enzyme in humans results in excessive dihydrotestosterone levels in peripheral tissues and hence suppression of androgen action by 5alpha-reductase inhibitors is a logical treatment for BPH as they inhibit the conversion of testosterone to dihydrotestosterone.
Preston and colleagues determine the association between 5α-reductase inhibitor use and development of high-grade or lethal prostate cancer.
Ad
related to: 5α reductase inhibitor